Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: flexiontherapeutics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/19/2021 | Outperform → Market Perform | Northland Capital Markets | |
10/19/2021 | $25.00 → $10.00 | Buy → Neutral | HC Wainwright & Co. |
10/12/2021 | $20.00 → $12.00 | Outperform → Market Perform | BMO Capital |
10/12/2021 | Strong Buy → Market Perform | Raymond James | |
10/12/2021 | $14.00 → $10.00 | Outperform → Neutral | Credit Suisse |
8/6/2021 | $8.00 → $6.00 | Neutral | Goldman Sachs |
8/5/2021 | $20.00 → $18.00 | Buy | Needham |